Update shared on19 Sep 2025
Fair value Increased 5.36%Twist Bioscience’s consensus price target increased to $42.14, as a higher future P/E suggests elevated growth expectations despite a decline in net profit margin.
What's in the News
- Collaborated with Synthetic Design Lab, utilizing proprietary tools to support SDL's research activities.
- Launched the customizable Twist Oncology DNA Comprehensive Genomic Profiling Panel, covering 562 genes and designed to serve clinical labs, academic centers, and biopharma; includes broad detection capabilities and partnerships with analytics providers.
- Provided Q4 and fiscal 2025 revenue guidance, forecasting $96–98 million for Q4 (14.5% YoY growth) and $374–376 million for the year (19.7% YoY growth).
- Introduced a humanized transgenic mouse model to enhance antibody discovery services, accelerating identification of fully human antibodies and expanding in vivo capabilities.
- Accelerated Express turnaround for all Twist Gene Fragments to as little as two business days and eliminated the adaptor removal fee, improving speed and cost-effectiveness for customers.
Valuation Changes
Summary of Valuation Changes for Twist Bioscience
- The Consensus Analyst Price Target has risen from $40.00 to $42.14.
- The Future P/E for Twist Bioscience has significantly risen from 33.21x to 39.64x.
- The Net Profit Margin for Twist Bioscience has significantly fallen from 16.06% to 14.17%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.